Education
About Us
Working with TipRanks
Follow Us
Medios AG (DE:ILM1)
XETRA:ILM1
Top Page
Medios AG
(XETRA:ILM1)
Rating:75Outperform
Price Target:
€13.50
▲(3.69%Upside)
Positive Factors
International Expansion
The internationalisation strategy of Medios is showing promising results with the successful integration of the Ceban acquisition.
Regulatory Environment
Higher profitability appears sustainable due to a more liberal regulatory framework in the Netherlands, giving the company greater entrepreneurial freedom.
Negative Factors
Earnings Forecast
Higher M&A-related one-offs, increased depreciation, and a higher tax rate have resulted in a lower EPS forecast.
Medios AG (ILM1) vs. iShares MSCI Germany ETF (EWG)
Market Cap
$331.57M
Dividend YieldN/A
Average Volume (3M)42.12K
Price to Earnings (P/E)22.1
Beta (1Y)0.74
Revenue Growth5.62%
EPS Growth-21.87%
CountryDE
Employees472
SectorHealthcare
Sector Strength39
IndustryMedical - Distribution
Share Statistics
EPS (TTM)0.25
Shares Outstanding25,505,724
10 Day Avg. Volume37,319
30 Day Avg. Volume42,117
Financial Highlights & Ratios
PEG Ratio1.42
Price to Book (P/B)0.64
Price to Sales (P/S)0.00
P/FCF Ratio12.41
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$19.78Price Target Upside51.94% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Medios AG Business Overview & Revenue Model
Company DescriptionMedios AG, together with its subsidiaries, engages in the wholesale of specialty pharmaceutical drugs in Germany. It operates through Pharmaceutical Supply and Patient-Specific Therapies segments. The Pharmaceutical Supply segment offers products on oncology, neurology, autoimmunology, ophthalmology, infectiology, and hemophilia diseases. The Patient-Specific Therapies segment manufactures medications for patients on behalf of pharmacies; and patient-specific therapies for dispensing individually dosed tablets. The company was founded in 2016 and is based in Berlin, Germany.
How the Company Makes MoneyMedios AG generates revenue through its core business of distributing specialty pharmaceuticals. The company's key revenue streams include the sale of specialty drugs to pharmacies and healthcare institutions. Medios AG benefits from strategic partnerships with pharmaceutical manufacturers, allowing it to offer a diverse range of specialty medications. The company also provides value-added services such as quality assurance and logistics support, which contribute to its revenue. Additionally, Medios AG's expertise in navigating regulatory frameworks enhances its ability to efficiently manage the supply chain, further strengthening its financial performance.
Medios AG Earnings Call Summary
Earnings Call Date:May 13, 2025
(Q3-2024)
| % Change Since: 6.72%|
Next Earnings Date:Aug 13, 2025
Earnings Call Sentiment Positive
The earnings call reflects a positive sentiment with strong financial performance and strategic advancements, despite some challenges in specific segments and increased costs related to acquisitions.Q3-2024 Updates
Positive Updates
Record Q3 Performance
The company posted its best quarter ever with significant earnings growth. EBITDA pre margin reached 5% for the first time, driven by PST and Ceban.
Strong Revenue and EBITDA Growth
Revenue grew by more than 4% to EUR 1.4 billion, with EBITDA pre increasing by more than 20% to EUR 55.8 million.
Successful Integration of Ceban
Ceban's integration is progressing smoothly, contributing significantly to the International Business segment.
Operational Cash Flow Surge
Operational cash flow increased by more than 100% to EUR 27.6 million compared to the same period last year.
Positive Future Strategy
The company is focusing on strengthening core business in Germany and expanding into other European countries, with plans to enter advanced therapies production.
Negative Updates
PST Segment Challenges
PST gross profit decreased due to deconsolidation of Kölsche Blister, regulatory headwinds, and increased performance-based payments.
Decreased EPS
Undiluted EPS for the first 9 months decreased from EUR 0.69 to EUR 0.43 due to increased depreciation, amortization, and higher interest payments.
Increased Operating Expenses
Other operating expenses rose due to higher legal and consulting costs, largely attributable to the Ceban acquisition and ERP implementation.
Equity Ratio Decline
The equity ratio decreased from 78.8% to 55.6% due to increased debt from the Ceban acquisition.
Company Guidance
During the Q3 2024 earnings call for Medios AG, the company provided several key financial metrics and guidance highlights. The company achieved a revenue growth of more than 4% to EUR 1.4 billion for the first nine months of 2024, with a significant EBITDA pre increase of over 20% to EUR 55.8 million. The EBITDA pre margin reached the 5% mark for the first time, driven by strong performances in the PST and Ceban segments. Operational cash flow more than doubled to EUR 27.6 million, and the company confirmed its guidance for 2024, anticipating full-year revenues between EUR 1.9 billion and EUR 2.1 billion and an EBITDA pre in the range of EUR 82 million to EUR 91 million. The company also noted inorganic growth due to the acquisition of Ceban, contributing EUR 47.3 million in revenue and EUR 9.8 million in EBITDA pre for the period June through October 2024. Additionally, Medios is focusing on strategic priorities, including expanding operations into other European countries and entering the production of advanced therapies, with a commitment to maintaining high-quality personalized medicines.Medios AG Financial Statement Overview
Summary
Medios AG demonstrates strong financial health with consistent revenue growth, improved gross and EBITDA margins, a robust balance sheet with low leverage, and efficient cash generation marked by substantial free cash flow growth. However, the slight decline in net profit margin and significant investing cash outflows are potential concerns.Income Statement
Medios AG has demonstrated a consistent upward trend in revenue, with a notable revenue growth rate of 5.51% from 2023 to 2024. The company's gross profit margin improved to 8.04% in 2024 from 6.09% in 2023, indicating better cost management. However, the net profit margin decreased slightly to 0.67% from 1.05%, suggesting a dip in overall profitability potentially due to increased operational costs or taxation. The EBIT margin remained stable at around 1.68%, while the EBITDA margin improved from 2.96% to 3.40%, showcasing enhanced operational efficiency.87
Very Positive
Balance Sheet
The balance sheet reflects strong equity growth, with stockholders' equity increasing to €510.19 million in 2024. The debt-to-equity ratio remains low at 0.47, indicating prudent leverage usage. The return on equity (ROE) is modest at 2.46%, but it indicates a reasonable return on shareholders' investments. The equity ratio stands at 54.60%, showcasing a robust capital structure with more than half of the assets financed by equity, implying financial stability.92
Very Positive
Cash Flow
Medios AG shows a substantial increase in free cash flow to €67.36 million in 2024 from €15.14 million in 2023, representing significant free cash flow growth. The operating cash flow to net income ratio is strong at 5.87, indicating efficient cash generation relative to net income. However, the large increase in free cash flow is partially offset by substantial investing cash outflows, which could imply significant reinvestment or capital expenditures.85
Very Positive
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.91B | 1.88B | 1.78B | 1.61B | 1.36B | 626.54M |
| Gross Profit | 154.37M | 151.46M | 108.63M | 106.87M | 68.48M | 37.58M |
| EBITDA | 74.20M | 64.00M | 52.82M | 51.33M | 34.68M | 13.12M |
| Net Income | 14.94M | 12.55M | 18.81M | 18.33M | 7.40M | 5.53M |
Balance Sheet | ||||||
| Total Assets | 929.17M | 934.36M | 594.75M | 575.96M | 524.14M | 194.54M |
| Cash, Cash Equivalents and Short-Term Investments | 89.34M | 106.00M | 71.04M | 79.21M | 168.43M | 19.79M |
| Total Debt | 221.58M | 238.37M | 17.15M | 17.63M | 49.71M | 19.23M |
| Total Liabilities | 412.38M | 424.17M | 125.95M | 127.91M | 129.98M | 52.11M |
| Stockholders Equity | 516.79M | 510.19M | 468.81M | 448.05M | 394.16M | 142.43M |
Cash Flow | ||||||
| Free Cash Flow | 26.75M | 67.36M | 15.14M | 32.06M | 48.70M | -42.98M |
| Operating Cash Flow | 33.14M | 73.67M | 16.41M | 37.12M | 61.52M | -38.12M |
| Investing Cash Flow | -221.50M | -222.28M | -16.57M | -86.54M | 17.36M | -5.88M |
| Financing Cash Flow | 164.08M | 183.80M | -8.01M | -39.80M | 69.76M | 51.14M |
Medios AG Technical Analysis
Positive
13.02
Price Trends
12.06
Positive
12.17
Positive
12.89
Positive
Market Momentum
0.26
Negative
66.08
Neutral
88.11
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:ILM1, the sentiment is Positive. The current price of 13.02 is above the 20-day moving average (MA) of 12.18, above the 50-day MA of 12.06, and above the 200-day MA of 12.89, indicating a bullish trend. The MACD of 0.26 indicates Negative momentum. The RSI at 66.08 is Neutral, neither overbought nor oversold. The STOCH value of 88.11 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:ILM1.
Medios AG Peers Comparison
Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | $331.57M | 22.07 | 2.99% | ― | 5.62% | -21.87% | |
52 Neutral | $7.45B | 0.27 | -61.87% | 2.30% | 16.62% | 1.04% | |
| €322.13M | 20.18 | 6.73% | 2.25% | ― | ― | ||
| €215.76M | ― | -59.35% | ― | ― | ― | ||
75 Outperform | €343.20M | 17.07 | 48.46% | 1.78% | 13.80% | 10.94% | |
71 Outperform | €280.54M | 17.40 | 14.61% | 3.33% | 7.23% | 58.37% | |
57 Neutral | €509.62M | 5.89 | -26.06% | ― | -10.32% | -250.76% |
* Healthcare Sector Average
Performance Comparison
DE:ILM1
Medios AG
13.02
-2.52
-16.22%
GB:0RAR
STRATEC Biomedical
26.50
-15.55
-36.98%
GB:0QW5
Heidelberg Pharma AG
4.52
1.87
70.57%
DE:FYB
Formycon AG
28.05
-27.15
-49.18%
DE:PSG
PharmaSGP Holding SE
28.20
7.04
33.27%
DE:M12
M1 Kliniken AG
14.60
-1.67
-10.26%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.